Polar Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Polar Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$19M	Sell	250,000 -255,000	-50%	-$25.8M	0.14%	137
2020 Q2	$62.3M	Buy	505,000 +305,000	+153%	+$30.3M	0.54%	57
2020 Q1	$16.9M	Buy	200,000 +80,000	+67%	+$6.89M	0.18%	139
2019 Q4	$10.1M	Sell	120,000 -5,000	-4%	-$378K	0.09%	199
2019 Q3	$8.43M	Buy	125,000 +10,000	+9%	+$770K	0.08%	210
2019 Q2	$9.85M	Hold	115,000	–	–	0.09%	192
2019 Q1	$10.2M	Sell	115,000 -39,370	-26%	-$3.65M	0.09%	181
2018 Q4	$13.1M	Hold	154,370	–	–	0.14%	156
2018 Q3	$15M	Sell	154,370 -57,130	-27%	-$5.7M	0.13%	164
2018 Q2	$19.9K	Sell	211,500 -800	-0.4%	-$70.1K	0.12%	155
2018 Q1	$17.2M	Sell	212,300 -42,500	-17%	-$3.65M	0.17%	151
2017 Q4	$22.7M	Sell	254,800 -11,911	-4%	-$1.04M	0.23%	125
2017 Q3	$24.8M	Buy	266,711 +22,500	+9%	+$1.99M	0.28%	114
2017 Q2	$22.2M	Sell	244,211 -238,089	-49%	-$21.7M	0.3%	114
2017 Q1	$42.3M	Buy	482,300 +67,800	+16%	+$6.03M	0.63%	48
2016 Q4	$34.3M	Buy	414,500 +145,000	+54%	+$12.5M	0.55%	48
2016 Q3	$24.9M	Sell	269,500 -32,155	-11%	-$3.03M	0.43%	73
2016 Q2	$23.5M	Sell	301,655 -49,527	-14%	-$4.21M	0.44%	74
2016 Q1	$29M	Buy	351,182 +325,460	+1,265%	+$26.5M	0.54%	51
2015 Q4	$2.69M	Buy	25,722 +13,603	+112%	+$1.42M	0.05%	204
2015 Q3	$1.28M	Buy	12,119 +216	+2%	+$28.9K	0.03%	237
2015 Q2	$1.63M	Buy	11,903 +1,940	+19%	+$240K	0.03%	235
2015 Q1	$1.24M	Buy	9,963 +2,088	+27%	+$221K	0.02%	245
2014 Q4	$712K	Buy	7,875 +3,910	+99%	+$325K	0.01%	248
2014 Q3	$286K	Sell	3,965 -2,299	-37%	-$151K	0.01%	260
2014 Q2	$390K	Buy	+6,264	New	+$378K	0.01%	252

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polar Capital's BMRN Position: Q3 2020 in Review

Polar Capital reduced its BioMarin Pharmaceuticals (BMRN) stake by 50% in Q3 2020, selling an estimated $25.8M and leaving 250,000 shares worth $19M. The position accounts for 0.14% of the portfolio, ranked #137.

Polar Capital first reported a position in BMRN in Q2 2014 and has held it in 26 quarters since. The position peaked at $62.3M in Q2 2020. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

Polar Capital held 250,000 shares of BioMarin Pharmaceuticals worth $19M as of Q3 2020.
Polar Capital sold 255,000 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $25.8M.
BioMarin Pharmaceuticals made up 0.14% of Polar Capital's portfolio in Q3 2020, its #137 holding.
Polar Capital first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 26 quarters since.
Polar Capital's BioMarin Pharmaceuticals position peaked at $62.3M in Q2 2020.
496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.